These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16838455)

  • 1. The Drug Enforcement Administration's final rule on theft and significant loss reporting: we can see more clearly now.
    Houck LK
    Food Drug Law J; 2006; 61(1):1-11. PubMed ID: 16838455
    [No Abstract]   [Full Text] [Related]  

  • 2. The International Academy of Compounding Pharmacists stepping up efforts to remedy problems caused by the U.S. Drug Enforcement Administration's "constructive transfer" policy.
    Miller DG
    Int J Pharm Compd; 2012; 16(2):94-6. PubMed ID: 23050319
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug enforcement and the Drug Enforcement Administration.
    Vogt HB
    S D Med; 2010 Jun; 63(6):201-2. PubMed ID: 20853589
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1991 Jun; 56(106):25025-7. PubMed ID: 10111144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Brazilian pharmaceutical market and the North American war effort].
    Quintaneiro T
    Estud Hist; 2002; (29):141-64. PubMed ID: 18030707
    [No Abstract]   [Full Text] [Related]  

  • 7. The Drug Enforcement Agency's position on "constructive transfer" under the Controlled Substances Act.
    Pore RD
    Int J Pharm Compd; 2012; 16(6):446-50. PubMed ID: 23259358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DEA grants prescriber numbers to certain Massachusetts pharmacists.
    J Pain Palliat Care Pharmacother; 2011; 25(3):297-9. PubMed ID: 21998842
    [No Abstract]   [Full Text] [Related]  

  • 9. An analysis tool to investigate theft or tampering of controlled substances.
    Kamerman R; Quirk B; Bluml B
    Hosp Pharm; 1992 Mar; 27(3):223-7. PubMed ID: 10116723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [History of the State Institute for Drug Control (1918-1983). History of the Institute for Drug Research (1918-1983)].
    Hanzlícek Z
    Cesk Farm; 1984 Mar; 33(2):83-91. PubMed ID: 6373028
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacists correcting schedule II prescriptions: DEA flip-flops continue.
    Abood RR
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):393-6. PubMed ID: 21133749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who is the guilty party? Rights, motherhood, and the problem of prenatal drug exposure.
    Zivi KD
    Law Soc Rev; 2000; 34(1):237-58. PubMed ID: 17094216
    [No Abstract]   [Full Text] [Related]  

  • 13. The Drug Enforcement Agency and DEA Form 104.
    Stratton WT
    Kans Med; 1994 Oct; 95(10):212, 214. PubMed ID: 7815771
    [No Abstract]   [Full Text] [Related]  

  • 14. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act.
    Cooper DE
    Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915
    [No Abstract]   [Full Text] [Related]  

  • 15. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Federal drug and narcotic legislation.
    Young JH
    Pharm Hist; 1995; 37(2):59-67. PubMed ID: 11639645
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-drug program for personnel engaged in specified aviation activities--Federal Aviation Administration. Final rule.
    Fed Regist; 1991 Sep; 56(172):43974-6. PubMed ID: 10170821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amendment of the fee exemption for federal, state and local government employees--DEA, Justice. Final rule.
    Fed Regist; 1994 Feb; 59(37):8859. PubMed ID: 10133414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarification of registration requirements for individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2006 Dec; 71(231):69478-80. PubMed ID: 17171847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation.
    Daemmrich A
    Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.